Home » Stocks » GLPG

Galapagos NV (GLPG)

Stock Price: $76.18 USD 0.12 (0.16%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $77.00 +0.82 (1.08%) May 14, 6:51 PM
Market Cap 4.99B
Revenue (ttm) 646.66M
Net Income (ttm) -372.48M
Shares Out 65.51M
EPS (ttm) -4.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $76.18
Previous Close $76.06
Change ($) 0.12
Change (%) 0.16%
Day's Open 75.28
Day's Range 75.13 - 76.56
Day's Volume 186,597
52-Week Range 70.77 - 227.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Galapagos NV (NASDAQ: GLPG) is chopping its pipeline to conserve cash while its business development team pursues a mission to find a “transformative” deal for the company. The company is ditching its I...

1 week ago - Benzinga

Mechelen, Belgium ; 30 April 2021 , 22.01 CET; regulated information – – Galapagos   NV (Euronext & NASDAQ : GLPG) announced today that its supervisory b oard created 2, 7 36,250 subscription rights und...

2 weeks ago - GlobeNewsWire

e-therapeutics PLC (LON:ETX) has reached two key milestones in its collaboration with Galapagos NV, triggering two payments to the company. The two operational and success-based milestones were defined ...

3 weeks ago - Proactive Investors

e-therapeutics plc (LON:ETX) has reached two key milestones in its collaboration with Galapagos NV, triggering two payments to the company. The two operational and success-based milestones were defined ...

3 weeks ago - Proactive Investors

Mechelen, Belgium; 08 April 2021; 22.01 CET; Galapagos (Euronext & Nasdaq; GLPG) announced today that Gilead and Galapagos signed an amendment to the share subscription agreement closed in 2019, extendi...

1 month ago - GlobeNewsWire

Mechelen, Belgium; 24 March 2021; 21.01 CET; Galapagos (Euronext & Nasdag; GLPG) announced today that its Supervisory Board has promoted Bart Filius to President and Chief Operating Officer (COO). Going...

1 month ago - GlobeNewsWire

Mechelen, Belgium; 19 March 2021, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

1 month ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are adv...

2 months ago - Newsfile Corp

Galapagos NV (NASDAQ: GLPG) has announced interim results from two ongoing safety studies investigating the effect of Jyseleca (filgotinib) on sperm parameters in males with inflammatory bowel disease (...

2 months ago - Benzinga

GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES

2 months ago - GlobeNewsWire

NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact ...

2 months ago - PRNewsWire

Despite some serious setbacks, this beaten-down biotech could be a terrific bargain at recent prices.

2 months ago - The Motley Fool

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are ...

3 months ago - Newsfile Corp

Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.

Other stocks mentioned: GILD
3 months ago - Zacks Investment Research

Despite solid signs of efficacy in mid-stage trials, the partners are shutting down all clinical trials with ziritaxestat.

Other stocks mentioned: GILD
3 months ago - The Motley Fool

Galapagos NV (NASDAQ: GLPG) and Gilead Sciences Inc (NASDAQ: GILD) have decided to stop the ISABELA Phase 3 studies evaluating ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF). All clin...

Other stocks mentioned: GILD
3 months ago - Benzinga

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical stud...

Other stocks mentioned: GILD
3 months ago - Business Wire

Foster City, CA and Mechelen, Belgium, 10 February 2021, 15.00 CET; regulated information –  Galapagos NV (Euronext & NASDAQ: GLPG) and Gilead Sciences (NASDAQ: GILD) today announced the decision to hal...

3 months ago - GlobeNewsWire

Mechelen, Belgium; 9 February 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc.

3 months ago - GlobeNewsWire

Gilead Sciences, Inc. (NASDAQ: GILD) and its R&D partner Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) received an upgrade each from Morgan Stanley. The Gilead, Galapagos Analyst: Matthew Harrison u...

Other stocks mentioned: GILD
3 months ago - Benzinga

Mechelen, Belgium; 11 January 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.

Other stocks mentioned: GILD
4 months ago - GlobeNewsWire

Mechelen, Belgium; 6 January 2021, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11-14, 2021.

4 months ago - GlobeNewsWire

MECHELEN, Belgium and KRAKOW, Poland, Jan. 4, 2021 /PRNewswire/ -- Galapagos NV [Euronext & NASDAQ: GLPG] and Selvita S.A. [WSE: SLV] announced today that the strategic transaction in which Selvita has ...

4 months ago - PRNewsWire

Mechelen, Belgium and Krakow, Poland – 04 January 2021, 22.01 TIME CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Selvita S.A. (WSE: SLV) announced today that the strategic transaction in which Selvit...

4 months ago - GlobeNewsWire

Due to the FDA's rejection of Filgotinib's 200 mg dosage for commercialisation in the US. Galapagos' earnings potential has been hampered severely. Yet, the current net cash position exceeds the company...

4 months ago - Seeking Alpha

New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are ...

4 months ago - Newsfile Corp

Mechelen, Belgium; 23 December 2020, 18.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) today announces that Onno van de Stolpe, CEO of Galapagos, has committed to make a personal €10 million donation t...

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 16, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are ...

4 months ago - Newsfile Corp

Gilead Sciences cut its losses on a rheumatoid arthritis treatment in partnership with Galapagos, sending GLPG stock tumbling on Wednesday. Gilead stock also fell less than 1%.

Other stocks mentioned: GILD
5 months ago - Investors Business Daily

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their ex...

Other stocks mentioned: GILD
5 months ago - Business Wire

-- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and...

Other stocks mentioned: GILD
5 months ago - GlobeNewsWire

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV (“Galapagos” or the “Company”) (NASDAQ: GLPG).   Such investors are advised to co...

5 months ago - GlobeNewsWire

Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.

Other stocks mentioned: BLUE, SAGE
5 months ago - The Motley Fool

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact ...

5 months ago - PRNewsWire

Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

5 months ago - GlobeNewsWire

Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first dosing in the new MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients wi...

5 months ago - GlobeNewsWire

Mechelen, Belgium; 30 November 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces positive topline results with its investigational GPR84 antagonist GLPG1205 in Proof-of-Concept Phase 2 t...

5 months ago - GlobeNewsWire

-Strengthening Selvita's position as one of the largest preclinical contract research organizations in Europe -

5 months ago - GlobeNewsWire

Galapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Mechelen, Belgium and Warsaw, Poland, 5 November 2020, 22.15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusive collabor...

6 months ago - GlobeNewsWire

Webcast presentation tomorrow, 06 November 2020, at 14.00 CET / 8 AM ET, www.glpg.com , +32 2 793 38 47 , code 8542327

6 months ago - GlobeNewsWire

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the application for a new indication to the...

Other stocks mentioned: GILD
6 months ago - Business Wire

Mechelen, Belgium; 27 October 2020, 16.15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) unveils the Toledo target family as a series of salt-inducible kinase inhibitors . Toledo exhibits a dual mode of a...

6 months ago - GlobeNewsWire

Galapagos is now tied tightly to Gilead. The stock price is near at the 52-week low.

6 months ago - Seeking Alpha

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: CBPO, HRTX, ILMN, IONS, RGNX, LGND
6 months ago - InvestorPlace

Galapagos Knee Osteoarthritis Data, And Other News: The Good, Bad And Ugly Of Biopharma

6 months ago - Seeking Alpha

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15)

Other stocks mentioned: AMRN
7 months ago - Benzinga

Mechelen, Belgium and Paris, France, 15 OCTOBER 2020, 22.01 CET; regulated information –Servier and Galapagos NV (Euronext & NASDAQ: GLPG) report that no signal of activity was observed in the topline r...

7 months ago - GlobeNewsWire

Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.

Other stocks mentioned: GILD
7 months ago - Zacks Investment Research

FOSTER CITY, Calif., & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today presented late-breaking data demonstrating sustained effi...

Other stocks mentioned: GILD
7 months ago - Business Wire

About GLPG

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690... [Read more...]

Industry
Biotechnology
IPO Date
May 6, 2005
CEO
Onno van de Stolpe
Employees
1,489
Stock Exchange
NASDAQ
Ticker Symbol
GLPG
Full Company Profile

Financial Performance

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Galapagos stock is "Hold." The 12-month stock price forecast is 94.73, which is an increase of 24.35% from the latest price.

Price Target
$94.73
(24.35% upside)
Analyst Consensus: Hold